A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Conditions: HIV Interventions: Biological: CD4BS CH505M5 Pr-NP1; Biological: CH505TF chTrimer; Biological: 3M-052-AF (labeled as AP 60-702); Biological: Aluminum Hydroxide Suspension (Alum); Biological: ACU-026-001-1 (labeled as empty LNP) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); Department of Health and Human Services; Duke University; Access to Advanced Health Institute (AAHI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials